ReviewWorld journal of clinical oncology2025
Current status and advances in the treatment of colorectal cancer with liver metastases.
Review in World journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and validation of a multivariable CT-based Delta-radiomics model for predicting efficacy to bevacizumab therapy in patients with colorectal liver metastases.Translational cancer research · 2026Article
- The role of targeted therapy in the management of colorectal cancer liver metastases: a systematic review and meta-analysis.Translational cancer research · 2026Article
- Diversion ostomy improves treatment tolerance, conversion surgery, and survival compared with self-expanding metal stenting in initially unresectable obstructive colorectal cancer.Frontiers in oncology · 2026Article
- Efficacy and survival prognosis analysis of surgical resection combined with targeted therapy in patients with colorectal cancer liver metastasis.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of colorectal cancer is gradually increasing, and a majority of patients are diagnosed with distant metastases at the time of initial diagnosis, with the liver being the most common site of metastasis. Unlike most malignant tumors, patients with distant metastases can still achieve favorable prognoses if both the primary tumor and liver metastases are surgically resected. With advances in systemic therapies, many patients with initially unresectable liver metastases from colorectal cancer can undergo systemic treatment to achieve conversion therapy, thereby gaining the opportunity for surgery. However, there is still no consensus on several issues, including the timing of systemic therapy before and after surgery, whether neoadjuvant therapy should be employed, and the choice between simultaneous or staged surgeries. This review aims to systematically describe the current treatment landscape for colorectal cancer with liver metastases and highlight several unresolved controversial issues, providing valuable insights for the diagnosis and treatment of colorectal liver metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.